Cyclin-dependent kinase inhibitors as anticancer drugs

0359286 - ÚEB 2011 RIV NL eng J - Článek v odborném periodiku
Kryštof, Vladimír - Uldrijan, S.
Cyclin-dependent kinase inhibitors as anticancer drugs.
Current Drug Targets. Roč. 11, č. 3 (2010), s. 291-302. ISSN 1389-4501. E-ISSN 1873-5592
Grant CEP: GA ČR GA204/08/0511; GA ČR GA301/08/1649; GA MŠMT(CZ) LC06077
Výzkumný záměr: CEZ:AV0Z50380511
Klíčová slova: CDK * protein kinase * inhibitor
Kód oboru RIV: CE - Biochemie
Impakt faktor: 3.061, rok: 2010

Poor therapeutic outcomes and serious side effects, together with acquired resistance to multiple drugs, are common problems of current cancer therapies. Therefore, there is an urgent need for new cancer-targeted drugs, which has led (inter alia) to the development of molecules that can specifically inhibit cyclin-dependent kinases (CDKs). In addition to their cell cycle regulatory functions, CDKs, especially CDK7 and CDK9, play important roles in the regulation of RNA polymerase II-mediated transcription. Here, we report on progress in the preclinical development of CDK inhibitors and their anticancer activities. Special attention is paid to the action mechanisms of the pan-specific CDK inhibitors flavopiridol and roscovitine, which have already entered phase II clinical trials as treatments for various tumours.
Trvalý link: http://hdl.handle.net/11104/0197097